Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information

Rhea-AI Summary

Elite Pharmaceuticals (OTCQB: ELTP) reported fiscal year 2026 results for the period ended March 31, 2026. Consolidated revenue was $148.9 million, up $64.8 million (~77%) year-over-year. Income from operations reached $49.1 million, an increase of $29.5 million (~151%), driven by Lisdexamfetamine, Oxycodone Acetaminophen, Naltrexone, and Phentermine products.

A conference call is scheduled for June 30, 2026 at 11:30 AM EDT with domestic and international dial-in options and an audio replay link.

Positive

• Fiscal 2026 revenue of $148.9 million, up $64.8 million (~77%) year-over-year
• Income from operations of $49.1 million, up $29.5 million (~151%) year-over-year
• Full-year contribution from Lisdexamfetamine supporting higher revenues
• Additional revenue from Oxycodone Acetaminophen tablets launched during Fiscal 2026
• Naltrexone and Phentermine tablets launched exclusively under Elite label boosting Elite-branded sales

Negative

• None.

News Market Reaction – ELTP

-7.57%

-7.57% Session close to close

In the Jun 30 session, ELTP declined 7.57%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT

Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 ("Fiscal 2026").

Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year. Income from operations was $49.1 million, an increase of $29.5 million or approximately 151% from the comparable period of the prior year. The increase in income from operations was primarily attributed to Elite’s Lisdexamfetamine, initially launched at the end of the prior fiscal year, having a full year contribution, revenues from Oxycodone Acetaminophen tablets launched during Fiscal 2026, combined with Naltrexone tablets and Phentermine tablets being launched exclusively under the Elite label during Fiscal 2026 and strong overall growth throughout the Elite label product lines.

Conference Call Information

Elite’s management will host a conference call to discuss the year-end 2026 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.

Date:	June 30, 2026
Time:	11:30 AM EDT
Dial-in numbers:	1-800-346-7359 (domestic) 1-973-528-0008 (international)
Conference number:	98840
Questions:	dianne@elitepharma.com Financial questions by 7:00 PM EDT on Monday, June 29, 2026
Audio Replay:	https://elite.irpass.com/events_presentations

 

The financial statements can be viewed for Elite's Fiscal Year 2026 on Form 10-K here.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationwide under the Elite Laboratories, Inc. label. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303269

FAQ

What were Elite Pharmaceuticals (OTCQB: ELTP) revenues for fiscal year ended March 31, 2026?

Elite Pharmaceuticals reported fiscal 2026 consolidated revenue of $148.9 million. According to Elite, this represents an increase of $64.8 million, or approximately 77%, compared with the prior fiscal year, reflecting expanded contributions from several Elite label generic products.

How much did Elite Pharmaceuticals (ELTP) income from operations grow in fiscal 2026?

Elite reported fiscal 2026 income from operations of $49.1 million. According to Elite, this was an increase of $29.5 million, or approximately 151%, versus the previous fiscal year, supported by new product launches and broader Elite label product growth.

Which products drove Elite Pharmaceuticals (ELTP) revenue growth in fiscal 2026?

Revenue growth was mainly driven by Lisdexamfetamine and several Elite label tablets. According to Elite, a full year of Lisdexamfetamine sales, plus Oxycodone Acetaminophen, Naltrexone, and Phentermine tablets, contributed to higher revenues across Elite’s branded generic portfolio.

When is Elite Pharmaceuticals' (ELTP) fiscal 2026 earnings conference call?

Elite scheduled its fiscal 2026 earnings conference call for June 30, 2026 at 11:30 AM EDT. According to Elite, investors can join using domestic dial-in 1-800-346-7359, international dial-in 1-973-528-0008, and conference number 98840.

How can ELTP investors submit questions for Elite Pharmaceuticals' June 30, 2026 call?

Investors should email financial questions to dianne@elitepharma.com by 7:00 PM EDT on Monday, June 29, 2026. According to Elite, submitted questions may be addressed during the June 30, 2026 conference call discussing fiscal 2026 results and business developments.

Where can investors listen to Elite Pharmaceuticals' (ELTP) conference call replay and view fiscal 2026 statements?

An audio replay will be available at https://elite.irpass.com/events_presentations. According to Elite, full financial statements for fiscal year 2026 can also be viewed in the company’s Form 10-K for the period ended March 31, 2026.